# A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

> **NCT03448042** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 123 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Runimotamab
- **DRUG:** Trastuzumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03448042
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-06
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03448042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03448042, "A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03448042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*